hVIVO plc announced that its consultancy services division,Venn Life Sciences("Venn"), has signed a contract with a major global pharmaceutical client worth 3.2 million over two years. The contract commences in January 2023, with the Venn team in Breda providing dedicated complex clinical pharmacokinetics ("PK") consultancy and programming services to this global pharmaceutical client on a number of drug development programmes across multiple therapeutic areas, to study the absorption, distribution and excretion of drugs within the body.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
30.06 GBX | +2.77% |
|
+10.15% | +26.84% |
07-17 | HVIVO reports 31% revenue jump; relocation to improve efficiencies | AN |
07-17 | Transcript : HVIVO plc - Analyst/Investor Day |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.84% | 259M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+49.11% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- VENN Stock
- News hVIVO plc
- HVIVO plc's Consultancy Services Division,Venn Life Sciences Signs Contract with a Major Global Pharmaceutical Client Worth €3.2 Million over Two Years